Abstract
Amplification of 8p11–12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11–12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray profiling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11–12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplification. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11–12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adelaide J, Chaffanet M, Imbert A, Allione F, Geneix J, Popovici C, van Alewijk D, Trapman J, Zeillinger R, Borresen-Dale AL, Lidereau R, Birnbaum D and Pebusque MJ . (1998). Genes Chromosomes Cancer, 22, 186–199.
Adelaide J, Huang HE, Murati A, Alsop AE, Orsetti B, Mozziconacci MJ, Popovici C, Ginestier C, Letessier A, Basset C, Courtay-Cahen C, Jacquemier J, Theillet C, Birnbaum D, Edwards PA and Chaffanet M . (2003). Genes Chromosomes Cancer, 37, 333–345.
Agresti A . (2002). Categorical Data Analysis. John Wiley & Sons Inc.: New Jersey.
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D . (2000). Nat. Genet., 25, 144–146.
Bautista S and Theillet C . (1998). Genes Chromosomes Cancer, 22, 268–277.
Bayani J, Brenton JD, Macgregor PF, Beheshti B, Albert M, Nallainathan D, Karaskova J, Rosen B, Murphy J, Laframboise S, Zanke B and Squire JA . (2002). Cancer Res., 62, 3466–3476.
Bhattacharya N, Chunder N, Basu D, Roy A, Mandal S, Majumder J, Roychowdhury S and Panda CK . (2004). Exp. Mol. Pathol., 76, 264–271.
Borrow J, Stanton Jr VP, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE and Housman DE . (1996). Nat. Genet., 14, 33–41.
Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R and Isaacs WB . (1996). Genomics, 35, 46–54.
Cabart P and Murphy S . (2001). J. Biol. Chem., 276, 43056–43064.
Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW and Mills GB . (2004). Nat. Med., 10, 1251–1256.
Clarke C, Titley J, Davies S and O'Hare MJ . (1994). Epithelial Cell Biol., 3, 38–46.
Courtay-Cahen C, Morris JS and Edwards PA . (2000). Genomics, 66, 15–25.
Davidson JM, Gorringe KL, Chin SF, Orsetti B, Besret C, Courtay-Cahen C, Roberts I, Theillet C, Caldas C, Edwards PA and Morris JS . (2000). Br. J. Cancer, 83, 1309–1317.
Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, Tomlinson IP and Carter NP . (2004). Cancer Res., 64, 4817–4825.
Elston CW and Ellis IO . (1991). Histopathology, 19, 403–410.
Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M and Nakamura Y . (1992). Cancer Res., 52, 5368–5372.
Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, Gorman P, Tomlinson IP and Carter NP . (2003). Genes Chromosomes Cancer, 36, 361–374.
Flanagan JM, Healey S, Young J, Whitehall V, Trott DA, Newbold RF and Chenevix-Trench G . (2004). Genes Chromosomes Cancer, 40, 247–260.
Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A and Kallioniemi OP . (2000). Cancer Res., 60, 4519–4525.
Garnis C, Coe BP, Zhang L, Rosin MP and Lam WL . (2004). Oncogene, 23, 2582–2586.
Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, deJong PJ, Zhao S, Liebman M and Weber BL . (2004). Genome Res., 14, 179–187.
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI and Griffiths K . (1982). Br. J. Cancer, 45, 361–366.
Huang HE, Chin SF, Ginestier C, Bardou VJ, Adelaide J, Iyer NG, Garcia MJ, Pole JC, Callagy GM, Hewitt SM, Gullick WJ, Jacquemier J, Caldas C, Chaffanet M, Birnbaum D and Edwards PA . (2004). Cancer Res., 64, 6840–6844.
Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP and Kallioniemi A . (2002). Cancer Res., 62, 6240–6245.
Ikegawa S, Isomura M, Koshizuka Y and Nakamura Y . (1999a). Cytogenet. Cell Genet, 85, 227–231.
Ikegawa S, Isomura M, Koshizuka Y and Nakamura Y . (1999b). J. Hum. Genet., 44, 337–342.
Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, Parry S, Budroni M, Palmieri G, Neville AM, O'Hare MJ and Lakhani SR . (2004). Cancer Res., 64, 3037–3045.
Ladomery M and Dellaire G . (2002). Ann. Hum. Genet., 66, 331–342.
Lindsay AJ, Hendrick AG, Cantalupo G, Senic-Matuglia F, Goud B, Bucci C and McCaffrey MW . (2002). J. Biol. Chem., 277, 12190–12199.
Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P, Elston CW, Nicholson RI, Blamey RW, Robertson JF and Ellis IO . (2002). Histopathology, 40, 215–222.
Naderi A, Ahmed AA, Barbosa-Morais NL, Aparicio S, Brenton JD and Caldas C . (2004). BMC Genom, 5, 9.
Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI and Robertson JF . (2001). Br. J. Cancer, 85, 1958–1963.
Pfaffl MW . (2001). Nucleic Acids Res., 29, e45.
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW and Albertson DG . (1998). Nat. Genet., 20, 207–211.
Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL and Brown PO . (2002). Proc. Natl. Acad. Sci. USA, 99, 12963–12968.
Pribill I, Speiser P, Leary J, Leodolter S, Hacker NF, Friedlander ML, Birnbaum D, Zeillinger R and Krainer M . (2001). Cancer Genet. Cytogenet., 129, 23–29.
Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA and Ethier SP . (2004). Cancer Res., 64, 40–47.
Rew DA . (2003). Eur. J. Surg. Oncol., 29, 764–765.
Sambrook J and Russell DW . (2001). Molecular cloning. A Laboratory Manual, Vol. 1. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp 6.26–26.27.
Schramm L, Pendergrast PS, Sun Y and Hernandez N . (2000). Genes Dev., 14, 2650–2663.
Segal E, Friedman N, Koller D and Regev A . (2004). Nat. Genet., 36, 1090–1098.
Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J, Adnane J, Longy M, Katsaros D, Sismondi P and Gaudray P . (1993). Genes Chromosomes Cancer, 7, 219–226.
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW and Haybittle JL . (1987). Br. J. Cancer, 56, 489–492.
Toomes C, Jackson A, Maguire K, Wood J, Gollin S, Ishwad C, Paterson I, Prime S, Parkinson K, Bell S, Woods G, Markham A, Oliver R, Woodward R, Sloan P, Dixon M, Read A and Thakker N . (2003). Genes Chromosomes Cancer, 37, 132–140.
Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B, Birnbaum D and Pebusque MJ . (1999). Oncogene, 18, 1903–1910.
Wang XZ, Jolicoeur EM, Conte N, Chaffanet M, Zhang Y, Mozziconacci MJ, Feiner H, Birnbaum D, Pebusque MJ and Ron D . (1999). Oncogene, 18, 5718–5721.
Yamamoto Y, Irie K, Asada M, Mino A, Mandai K and Takai Y . (2004). Oncogene, 23, 3889–3897.
Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ and Sealfon SC . (2002). Nucleic Acids Res., 30, e48.
Acknowledgements
We thank Celine Courtay-Cahen for characterization of the BACs, Rachel Lyman for preparation of cell lines, Ahmed Ahmed for revision of ovarian tumors staging and grading, Ian Giddings and Jeremy Clark for help printing the CGH-array and David Bowtell for reviewing the manuscript. This work was supported by Cancer Research UK (CRUK), Wellbeing, the Biotechnology and Biological Sciences Research Council (BBSRC) and The Cambridge-MIT Institute (CMI). JDB is a CRUK Senior Clinical Research Fellow.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Garcia, M., Pole, J., Chin, SF. et al. A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. Oncogene 24, 5235–5245 (2005). https://doi.org/10.1038/sj.onc.1208741
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208741
Keywords
This article is cited by
-
Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer
BMC Cancer (2019)
-
Transcription factor Sp1 is necessary and functional in regulating expression of oncogene ZNF703
Genes & Genomics (2017)
-
A pilot study on the prevalence of DNA palindromes in breast cancer genomes
BMC Medical Genomics (2016)
-
Evolution of the NET (NocA, Nlz, Elbow, TLP-1) protein family in metazoans: insights from expression data and phylogenetic analysis
Scientific Reports (2016)
-
A novel ER–microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression
Cell Discovery (2015)